Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 25 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with akm clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 25 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with akm clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 25 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with pharmacor clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 25 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with pharmacor clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 200 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with akm clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 200 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with akm clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 200 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with pharmacor clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 200 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with pharmacor clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 100 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with akm clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - clozapine, quantity: 100 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; povidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate - treatment with akm clozapine is indicated only in people with treatment resistant schizophrenia, i.e. people with schizophrenia who are non-responsive to, or intolerant of other antipsychotic drugs.,non-responsiveness is defined as lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations.,intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse effects (extrapyramidal side effects or tardive dyskinesia).